Equities

Hikma Pharmaceuticals PLC

HIK:LSE

Hikma Pharmaceuticals PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,950.00
  • Today's Change78.00 / 4.17%
  • Shares traded406.77k
  • 1 Year change11.05%
  • Beta0.3862
Data delayed at least 20 minutes, as of Nov 22 2024 16:38 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Hikma Pharmaceuticals PLC had little change in net income (from 188.00m to 190.00m) despite revenues that grew 14.22% from 2.52bn to 2.88bn. A contributing factor has been an increase in the cost of goods sold as a percent of sales from 49.74% to 51.06%.
Gross margin47.40%
Net profit margin9.61%
Operating margin14.78%
Return on assets6.13%
Return on equity12.74%
Return on investment8.47%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Hikma Pharmaceuticals PLC fell by 65.00m. However, the company earned 608.00m from its operations for a Cash Flow Margin of 21.15%. In addition the company used 333.00m on investing activities and also paid 337.00m in financing cash flows.
Cash flow per share1.71
Price/Cash flow per share10.92
Book value per share8.22
Tangible book value per share4.28
More ▼

Balance sheet in USDView more

Hikma Pharmaceuticals PLC has a Debt to Total Capital ratio of 35.68%, a lower figure than the previous year's 49.84%.
Current ratio1.66
Quick ratio0.9775
Total debt/total equity0.5582
Total debt/total capital0.3568
More ▼

Growth rates in USD

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 30.11% and 2.26%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg)2.12%
Div growth rate (5 year)14.03%
Payout ratio (TTM)61.40%
EPS growth(5 years)-6.02
EPS (TTM) vs
TTM 1 year ago		93.85
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.